Reversal of several aging pathways & diseases

Phil Newman

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

George Church

Founding Core Faculty & Lead, Synthetic Biology, Wyss Institute at Harvard University

Reversal of several aging pathways & diseases

Phil Newman

Editor-in-Chief

Phil is Editor-in-Chief Longevity.Technology and founder of First Longevity which brings together international investors and Longevity start-ups.

In his career, Phil has held c-level management positions; applying his marketing and business development expertise into these tech sectors: Longevity; IoT; AI; Medical Devices; Biopharma; 3D Manufacturing; Smartgrid and Sustainability.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Moonwalk raises $70m for adipose-targeted RNAi

Rznomics brings RNA editing into Lilly’s San Diego biotech hub

Celularity lands $300m MuseCell manufacturing deal

Daewoong wins US patent nod for antiaging mRNA

Brain health ‘collaboratory’ focuses on non-invasive Alzheimer’s therapy

Perplexity enters the consumer health AI arena

Startup targets ‘untreatable blindness’ with bionic eye system

Science Corp lands $230m to commercialize vision restoration chip

MUSCLE: FLT’s revolutionary AI-powered supplement for strength and longevity

Ergothioneine: The little-known molecule transforming brain health and longevity

COGNITION: FLT’s new brain-boosting supplement that’s redefining mental performance

7 Best l-glutamine supplements to buy in 2024

From World Cup Champions to Longevity Champions

Reversal of several aging pathways & diseases

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

George Church

Founding Core Faculty & Lead, Synthetic Biology, Wyss Institute at Harvard University

Reversal of several aging pathways & diseases

You might also like

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Rznomics brings RNA editing into Lilly’s San Diego biotech hub

Celularity lands $300m MuseCell manufacturing deal

Daewoong wins US patent nod for antiaging mRNA

Perplexity enters the consumer health AI arena

Startup targets ‘untreatable blindness’ with bionic eye system

Science Corp lands $230m to commercialize vision restoration chip

Ergothioneine: The little-known molecule transforming brain health and longevity

COGNITION: FLT’s new brain-boosting supplement that’s redefining mental performance

7 Best l-glutamine supplements to buy in 2024

Lone Korean biotech nears $81m antiaging prize

Biograph builds dedicated women’s preventive health arm

Longevity.Technology wants to make longevity make sense

Reversal of several aging pathways & diseases

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

George Church

Founding Core Faculty & Lead, Synthetic Biology, Wyss Institute at Harvard University

Reversal of several aging pathways & diseases

You might also like

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

The latest longevity science, investment, innovation and insight, delivered every morning.